SecSonar.com

Arvinas, Inc. (ARVN)

Arvinas, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Arvinas, Inc. (ARVN) is a Biotechnology company based in US with a market capitalization of $572M. Revenue declined 0.3% year-over-year and free cash flow was negative at -$275.7M. This page tracks ARVN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 430 employees · IPO Sep 27, 2018

Valuation

Valuation & price

$9.08 · as of May 17, 2026 · -34.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.32

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$13.83$10.13$6.43Jul 25Dec 25Jul 26Jul 7, 25$7.79Jul 9, 25$8.23Jul 11, 25$7.79Jul 15, 25$7.40Jul 17, 25$7.76Jul 21, 25$7.52Jul 23, 25$7.87Jul 25, 25$7.84Jul 29, 25$7.48Jul 31, 25$7.44Aug 4, 25$7.53Aug 6, 25$6.43Aug 11, 25$6.59Aug 13, 25$7.09Aug 15, 25$7.09Aug 19, 25$7.14Aug 21, 25$7.30Aug 25, 25$7.48Aug 27, 25$8.08Aug 29, 25$7.73Sep 3, 25$7.90Sep 5, 25$7.83Sep 9, 25$8.00Sep 11, 25$7.81Sep 16, 25$7.64Sep 18, 25$7.72Sep 22, 25$7.53Sep 24, 25$7.73Sep 26, 25$8.27Sep 30, 25$8.52Oct 2, 25$9.27Oct 6, 25$9.62Oct 8, 25$9.75Oct 10, 25$9.46Oct 14, 25$9.41Oct 16, 25$9.68Oct 21, 25$9.66Oct 23, 25$9.16Oct 27, 25$9.65Oct 29, 25$9.59Oct 31, 25$10.14Nov 4, 25$9.54Nov 6, 25$10.00Nov 10, 25$11.19Nov 12, 25$10.41Nov 14, 25$10.57Nov 18, 25$12.99Nov 20, 25$11.02Nov 25, 25$12.12Nov 28, 25$12.59Dec 2, 25$11.66Dec 4, 25$12.55Dec 8, 25$13.32Dec 10, 25$12.98Dec 12, 25$12.58Dec 16, 25$11.90Dec 18, 25$11.28Dec 22, 25$12.32Dec 24, 25$12.17Dec 29, 25$11.90Jan 2, 26$11.47Jan 6, 26$11.83Jan 8, 26$12.18Jan 12, 26$12.15Jan 14, 26$12.20Jan 16, 26$12.20Jan 21, 26$12.60Jan 23, 26$12.89Jan 27, 26$13.62Jan 29, 26$13.38Feb 2, 26$13.83Feb 4, 26$13.39Feb 9, 26$13.29Feb 11, 26$13.09Feb 13, 26$11.65Feb 18, 26$11.82Feb 20, 26$11.99Feb 24, 26$12.37Feb 26, 26$13.38Mar 2, 26$13.39Mar 4, 26$13.76Mar 6, 26$13.60Mar 10, 26$13.83Mar 12, 26$12.48Mar 17, 26$12.01Mar 19, 26$11.17Mar 23, 26$10.32Mar 25, 26$10.92Mar 27, 26$10.10Mar 31, 26$10.60Apr 2, 26$10.85Apr 7, 26$11.37Apr 9, 26$11.17Apr 13, 26$10.58Apr 15, 26$10.97Apr 17, 26$11.00Apr 22, 26$10.63Apr 24, 26$10.44Apr 28, 26$10.22Apr 30, 26$9.90May 4, 26$10.78May 6, 26$10.26May 8, 26$10.11May 12, 26$9.57May 14, 26$9.42May 18, 26$8.78May 20, 26$9.10May 22, 26$9.09May 28, 26$8.84Jun 1, 26$8.58Jun 3, 26$7.70Jun 5, 26$7.42Jun 9, 26$7.21Jun 11, 26$7.09Jun 15, 26$7.49Jun 17, 26$7.67Jun 22, 26$7.74Jun 24, 26$8.05Jun 26, 26$8.00Jul 2, 26$8.39
$6.2452-week range$13.83
Loading valuation history…

Fundamentals

Key fundamentals

$572M

Market cap

-0.3%

Revenue growth (YoY)

98.0%

Gross margin

-$275.7M

Free cash flow (USD)

-$676.5M

Net debt

Net cash position

-9.7%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$6.7MFY 2017$7.6MFY 2018$14.3MFY 2019$43.0MFY 2020$25.9MFY 2021$53.6MFY 2022$131.4MFY 2023$78.5MFY 2024$263.4MFY 2025$262.6M
$6.7M$262.6M

Free cash flow by year

2016 → 2025

FY 2016$-19.7MFY 2017$4.1MFY 2018$-18.9MFY 2019$-46.9MFY 2020$-96.2MFY 2021$554.7MFY 2022$-280.3MFY 2023$-350.7MFY 2024$-261.1MFY 2025$-275.7M
-$19.7M-$275.7M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 202598.0%
100.0%98.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

1

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 11, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 25, 2026Filing
  • Insider sellInsider Sell $46KSaik Andrew · Chief Financial Officer · $46.5KJun 24, 2026Filing
  • 8-K eventCMO DepartureJun 22, 2026Filing
  • 8-K eventLicense Agreement EffectiveJun 16, 2026Filing
  • 8-K eventInvestor Presentation ScheduledJun 2, 2026Filing
  • 8-K eventLicense Agreement SignedMay 12, 2026Filing
  • 8-K eventEarnings ReleaseMay 12, 2026Filing
  • Quarterly report10-Q FiledMay 11, 2026Filing
  • 8-K eventFDA ApprovalMay 1, 2026Filing

Questions

Frequently asked questions

What is Arvinas, Inc.'s market cap?

Arvinas, Inc. (ARVN) has a market capitalization of $572M.

What is ARVN's P/E ratio?

A meaningful P/E ratio is not available for ARVN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ARVN's price-to-book (P/B) ratio?

ARVN trades at 1.32 times book value per share.

Are insiders buying ARVN stock?

SEC Form 4 filings show no open-market insider buys at Arvinas, Inc. in the last 90 days (1 sell).

Same arena

Related companies in Biotechnology

GYRE

Gyre Therapeutics, Inc.

$572.7M

VALN

Valneva SE

$563.3M

RIGL

Rigel Pharmaceuticals, Inc.

$562.1M

CTMX

CytomX Therapeutics, Inc.

$582.2M

MDXG

MiMedx Group, Inc.

$553.3M

ACRS

Aclaris Therapeutics, Inc.

$546.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.